Profil
Ronald L.
Shazer worked as a Director of Clinical Research Oncology at Bristol Myers Squibb Co. from 2011 to 2013, Director of Clinical Research at Exelixis, Inc. from 2007 to 2009, Head of Clinical Development at Arena Pharmaceuticals, Inc. from 2010 to 2011, Senior Director of Clinical Lead Oncology at Pfizer Inc. from 2015 to 2016, Chief Medical Officer at TRACON Pharmaceuticals, Inc. from 2015 to 2016, and Chief Medical Officer & Senior Vice President at Rebus Holdings, Inc. from 2016 to 2018.
He received his undergraduate degree from the University of California San Diego, his doctorate from New York Medical College, and his MBA from UCLA Anderson School of Management.
Anciens postes connus de Ronald Shazer
| Sociétés | Poste | Fin |
|---|---|---|
| REBUS HOLDINGS, INC. | Directeur Technique/Scientifique/R&D | 12/02/2018 |
| TRACON PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 05/08/2016 |
| PFIZER, INC. | Corporate Officer/Principal | 01/08/2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/08/2013 |
| ARENA PHARMACEUTICALS | Corporate Officer/Principal | 01/08/2011 |
Formation de Ronald Shazer
| University of California San Diego | Undergraduate Degree |
| New York Medical College | Doctorate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| TRACON PHARMACEUTICALS, INC. | Health Technology |
| REBUS HOLDINGS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| EXELIXIS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |